Preferred Label : daratumumab;

MeSH note : an antineoplastic agent;

MeSH hyponym : humax-CD 38;

Is substance : O;

UNII : 4Z63YK6E0E;

Details


Main resources

You can consult :


https://ansm.sante.fr/tableau-marr/daratumumab
2023
false
false
false
France
French
guideline
patient education handout
risk management
daratumumab
daratumumab
Laboratory test related to immunohematology (procedure)
Laboratory test interference
immunologic tests
hematologic tests

---
https://www.has-sante.fr/jcms/p_3320599/fr/darzalex-daratumumab-amylose-systemique-a-chaines-legeres
2022
France
evaluation of the transparency committee
Darzalex
amyloid deposition, nos
chain
daratumumab
daratumumab
amyloidosis, nos
amylose

---
https://www.has-sante.fr/jcms/p_3334268/fr/darzalex-daratumumab-myelome-multiple
2022
France
evaluation of the transparency committee
multiple myeloma
daratumumab
Myeloma
Darzalex
Myeloma
daratumumab
multiple myeloma

---
https://www.has-sante.fr/jcms/p_3322754/fr/darzalex-daratumumab
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
daratumumab
antineoplastic combined chemotherapy protocols
multiple myeloma
Dara-Pd Regimen
antineoplastic agents
adult
evaluation of the transparency committee
daratumumab

---
https://www.has-sante.fr/jcms/p_3320599/fr/darzalex-amylose-systemique-a-chaines-legeres-daratumumab
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
Immunoglobulin Light-chain Amyloidosis
injections, subcutaneous
daratumumab
antineoplastic combined chemotherapy protocols
Bortezomib/Cyclophosphamide/Daratumumab/Dexamethasone Regimen
evaluation of the transparency committee
daratumumab

---
https://www.has-sante.fr/jcms/p_3399882/fr/darzalex-daratumumab-myelome-multiple
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
daratumumab
antineoplastic combined chemotherapy protocols
antineoplastic agents
dexamethasone
Lenalidomide
adult
Bortezomib
Refractory Multiple Myeloma
injections, subcutaneous
infusions, intravenous
evaluation of the transparency committee
daratumumab
multiple myeloma

---
https://has-sante.fr/jcms/p_3292242/fr/decision-n-2021-0262/dc/sem-du-7-octobre-2021-du-college-de-la-haute-autorite-de-sante-constatant-l-impact-significatif-du-produit-darzalex-daratumumab-1800-mg-sur-les-depenses-de-l-assurance-maladie
2021
France
public health guidelines
Darzalex
Insurance
health
health expenditures
7-methylbenzanthracene
daratumumab
daratumumab
disease, nos
Diseases
expenditures
schools
insurance, health
Disease

---
https://www.has-sante.fr/jcms/p_3183518/fr/darzalex
2020
false
false
false
France
insurance, health, reimbursement
treatment outcome
daratumumab
daratumumab
adult
multiple myeloma
antineoplastic combined chemotherapy protocols
Bortezomib
thalidomide
dexamethasone
antineoplastic agents
infusions, intravenous
peripheral blood stem cell transplantation
transplantation, autologous
evaluation of the transparency committee
antibodies, monoclonal

---
https://has-sante.fr/jcms/p_3183497/fr/darzalex-daratumumab
2020
France
evaluation of the transparency committee
daratumumab
Darzalex
daratumumab

---
https://has-sante.fr/jcms/p_3183488/fr/darzalex-daratumumab
2020
France
evaluation of the transparency committee
indicators
indicators and reagents
daratumumab
daratumumab
Darzalex
traction
indication of

---
https://www.has-sante.fr/jcms/p_3200943/fr/darzalex
2020
false
false
false
France
treatment outcome
insurance, health, reimbursement
multiple myeloma
antineoplastic agents
daratumumab
survival analysis
injections, subcutaneous
Product containing only daratumumab in parenteral dose form (medicinal product form)
evaluation of the transparency committee
daratumumab
antibodies, monoclonal
antibodies, monoclonal

---
https://www.has-sante.fr/portail/jcms/c_2967184/fr/darzalex
2019
false
false
false
France
adult
multiple myeloma
antineoplastic combined chemotherapy protocols
infusions, intravenous
antineoplastic agents
daratumumab
Bortezomib
melphalan
prednisone
survival analysis
treatment outcome
evaluation of the transparency committee
Darzalex
daratumumab
antibodies, monoclonal
daratumumab
antibodies, monoclonal

---
https://www.has-sante.fr/portail/jcms/c_2808583/fr/darzalex-daratumumab-anticorps-monoclonal-en-association
https://www.has-sante.fr/portail/jcms/c_2808583/fr/darzalex-en-association
2019
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
treatment outcome
antineoplastic combined chemotherapy protocols
daratumumab
daratumumab
antineoplastic agents
antineoplastic agents
multiple myeloma
disease-free survival
survival analysis
adult
daratumumab
antibodies, monoclonal
antibodies, monoclonal

---
https://ansm.sante.fr/informations-de-securite/darzalex-v-daratumumab-risque-de-reactivation-du-virus-de-lhepatite-b
2019
false
false
false
France
French
hepatitis B
daratumumab
Hepatitis B reactivation
virus activation
hepatitis B
mass screening
hepatitis B
pharmacovigilance note
guidelines for drug use
daratumumab
continuity of patient care
risk
hepatitis b virus
antibodies, monoclonal

---
https://www.has-sante.fr/portail/jcms/c_2808595/fr/darzalex-daratumumab-anticorps-monoclonal-monotherapie
https://www.has-sante.fr/portail/jcms/c_2808595/fr/darzalex-monotherapie
2019
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
adult
multiple myeloma
recurrence
daratumumab
daratumumab
daratumumab
antineoplastic agents
antineoplastic agents
treatment outcome
antibodies, monoclonal
antibodies, monoclonal

---
DARZALEX (daratumumab) and Hepatitis B Virus Reactivation
http://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2019/69402a-fra.php
2019
false
false
false
Canada
French
English
pharmacovigilance note
daratumumab
Hepatitis B reactivation
hepatitis B
continuity of patient care
virus activation
hepatitis b virus
mass screening
hepatitis B
antineoplastic agents
antibodies, monoclonal

---
https://www.pharmactuel.com/index.php/pharmactuel/article/view/1190
2018
false
false
false
false
Canada
French
critical appraisal or critical reading
Acne fulminans
daratumumab
data collection
multiple myeloma
Myeloma
Induced fracture
dexamethasone
intractable
Myeloma
therapeutics
treaties
combined
multiple myeloma
international cooperation
antibodies, monoclonal
thalidomide
Lenalidomide

---
https://www.pharmactuel.com/index.php/pharmactuel/article/view/1209
2018
false
false
false
Canada
French
journal article
treatment outcome
disease-free survival
carfilzomib
elotuzumab
daratumumab
antineoplastic agents
antineoplastic agents
ixazomib
recurrence
multiple myeloma
oligopeptides
antibodies, monoclonal, humanized
antibodies, monoclonal
boron compounds
glycine
glycine
indoles
hydroxamic acids
Panobinostat

---
https://www.jle.com/fr/revues/abc/e-docs/interferences_serologiques_du_traitement_du_myelome_multiple_par_daratumumab_anti_cd38_a_propos_dun_cas_309729/article.phtml
10.1684/abc.2017.1237
2017
false
false
false
France
French
case reports
french abstract
biology
autoimmune diseases
treaties
febrile convulsion
therapeutics
clinical
daratumumab
serologic
multiple myeloma
Myeloma
biologic
proband
serology
ADP-ribosyl Cyclase 1
multiple myeloma
case study
international cooperation
case reports
antibodies, monoclonal

---
Summary Basis of Decision (SBD) for Darzalex
Daratumumab, 20 mg/mL, solution, intravenous
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00321
2016
false
false
false
Canada
French
English
daratumumab
daratumumab
infusions, intravenous
antineoplastic agents
antineoplastic agents
drug approval
canada
multiple myeloma
summary of product characteristics
risk assessment
drug evaluation
treatment outcome
CD38 protein, human
daratumumab
antibodies, monoclonal
antibodies, monoclonal
membrane glycoproteins
ADP-ribosyl Cyclase 1

---
https://www.ema.europa.eu/medicines/human/EPAR/Darzalex
2016
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
antibodies, monoclonal
daratumumab
drug approval
europe
treatment outcome
product surveillance, postmarketing
antineoplastic agents
antineoplastic agents
multiple myeloma
orphan drug production
adult
infusions, intravenous
CD38 protein, human
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
daratumumab
daratumumab
antibodies, monoclonal
membrane glycoproteins
ADP-ribosyl Cyclase 1

---
Nous contacter.
19/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.